Iovance Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Iovance Biotherapeutics

27/02/2025 22:01

Iovance Biotherapeutics Inc IOVA.OQ reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -45 cents.  The mean expectation of fourteen analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -36 cents to -23 cents per share.

Revenue rose 15,189.2% to $73.69 million from a year ago; analysts expected $72.39 million.

Iovance Biotherapeutics Inc's reported EPS for the quarter was a loss of 26 cents​.

The company reported a quarterly loss of $78.56 million.

Iovance Biotherapeutics Inc shares had fallen by 27.7% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $23.00

This summary was machine generated from LSEG data February 27 at 10:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.27
-0.26
Beat
Sep. 30 2024
-0.30
-0.28
Beat
Jun. 30 2024
-0.35
-0.34
Beat
Mar. 31 2024
-0.42
-0.42
Met